Production (Stage)
Channel Therapeutics Corporation
CHRO
$1.22
-$0.0065-0.53%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.36M | -7.96M | -10.07M | -9.79M | -8.98M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 180.60K | 692.00K | 535.60K | 744.60K | 762.10K |
| Total Other Non-Cash Items | 1.63M | 1.44M | 4.12M | 4.19M | 4.18M |
| Change in Net Operating Assets | 1.12M | 34.70K | -71.30K | -694.70K | 1.23M |
| Cash from Operations | -4.43M | -5.79M | -5.48M | -5.56M | -2.80M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 786.20K | 536.20K | 865.00K | 1.96M | 600.00K |
| Total Debt Repaid | 0.00 | -214.80K | -214.80K | -214.80K | -214.80K |
| Issuance of Common Stock | 82.60K | 6.05M | 6.23M | 6.23M | 6.23M |
| Repurchase of Common Stock | -75.00K | -75.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -91.50K | -166.50K | -91.50K | -91.50K |
| Cash from Financing | 793.80K | 6.21M | 6.71M | 7.88M | 6.52M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.64M | 417.00K | 1.23M | 2.32M | 3.72M |